Communicators

are winners!

More News

06.02.2024
Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program
18.01.2024
Phase I/II Clinical Trial Results for Diabetic Foot Infection Treatment - Positive Human Efficacy Data to Support Site Expansion
14.12.2023
R&D Finding awarded & positive Data from Neisseria gonorrhoeae Animal Model Study
23.11.2023
Canadian Patent Granted for RECCE® Anti-Infectives
07.11.2023
First Subjects of Recruited Cohort Dosed - Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
24.10.2023
Safety Committee Approves Faster Infusion Rate of 15 Minutes in Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
12.09.2023
Recce Pharmaceuticals: Strongly Supported $8m Placement – Launches $3m Entitlement Offer to Shareholders
06.09.2023
RECCE® Trademark Registered – Vietnam
01.09.2023
Recce Pharmaceuticals Limited: Additional Positive Patient Cases – Special Access Scheme
21.08.2023
Recce Pharmaceuticals Ltd. - Phase I/II Clinical Trial for the Treatment of Burn Wound Infections – Stage 1 Data Analysis Complete